Plasma complement component 4 increases in patients with major depressive disorder

Area of Science:

• Neuroscience
• Immunology
• Psychiatry

Background:

• Major depressive disorder (MDD) is associated with inflammation, but findings on inflammatory factors are inconsistent.
• Complement components, like complement component 4 (C4), may influence MDD pathophysiology through inflammatory pathways.
• C4's role in neural synapse elimination and its association with schizophrenia suggest potential involvement in MDD.

Purpose of the Study:

• To investigate plasma concentrations of C4 and key inflammatory factors in patients with MDD compared to healthy controls.
• To explore the correlation between C4, inflammatory factors, and depressive/anxiety symptoms.
• To assess the effect of antidepressant medication on plasma C4 levels in MDD patients.

Main Methods:

• Plasma C4 and inflammatory factor levels (IL-1β, IL-6, IL-8, IL-10, IFN-α, IFN-γ, TNF-α) were measured in 53 MDD patients and 60 healthy controls.
• Plasma samples from 17 MDD patients post-antidepressant treatment were also analyzed.
• Statistical analyses were performed to compare groups and assess correlations.

Main Results:

• Peripheral C4 levels were significantly higher in MDD patients than in healthy controls.
• No significant correlations were found between inflammatory factors or C4 levels and the severity of depressive or anxiety symptoms.
• Antidepressant medication led to a significant reduction in plasma C4 levels in MDD patients.

Conclusions:

• Elevated C4 in MDD supports its potential role in the disorder's pathophysiology.
• C4 may serve as a candidate biomarker for MDD research.
• Further investigation into C4's specific mechanisms in MDD is warranted.